People participating in clinical trials tolerated the medication well, although some did experience mild reactions
This has led to patients seeking access to these medications through online companies or compounding pharmacies
Son JW, Lee SS, Kim SR, Yoo SJ, Cha BY, Son HY, et al
The distribution of estimated life-years free of new and recurrent CVD events gained with semaglutide was wide, reflecting variation in absolute benefit gained with semaglutide between patients, with those with higher baseline risk and who were younger at treatment initiation experiencing the greatest absolute benefit. Researchers collected data from the SUSTAIN 6 and PIONEER 6 randomized, double-blind, placebo-controlled trials, both of which evaluated the effects of semaglutide (Wegovy, Novo Nordisk) in people with type 2 diabetes at high risk for CVD